India's Aurobindo Pharma intends to beef up its manufacturing capacity over the next three years. According to LiveMint, it will build three new plants, the costs of which will be included in its 900 crore rupee ($137 million) capital outlay plan for the next year. The publication said the plans include an oral solid finished dosages facility at Naidupeta, an oral finished dosage facility in Visakhapatnam, and a semisynthetic penicillin plant at Jadcherla, near Hyderabad. Report